Biotech & Medtech
Biotech & Medtech news — Thursday 15 October 2026
28 stories from 5 sources, every one in English. Each links to its publisher.
-
Rosarium Health Forms Home Modification Partnership with Anthem Medi-Cal
Rosarium Health partnered with Anthem Medi-Cal to provide home safety modifications for eligible members. The post Rosarium Health Forms Home Modification Partnership with Anthem Medi-Cal appeared first on MedCity News .
-
Trump administration advances plan for peptide drugs favored by RFK Jr.
WASHINGTON — U.S. health officials are moving ahead with a plan to allow specialty pharmacies to produce certain peptides , a class of largely unregulated injections that have become popular among followers of Health Secretary Robert F…
-
Merck and Moderna have ‘lot of exploring to do’ after initial cancer vaccine success
After public school teacher Gary Keblish was diagnosed with melanoma in 2019, a surgeon cut out the tumor. But he wasn’t out of the woods. In some patients, melanoma aggressively recurs after surgery, so his doctors referred him to a new…
-
AI Biotech Iambic Gets $150M in IPO Cash for ‘Molecular Superintelligence’ Drug R&D
Iambic Therapeutics, an AI-enabled biotech company, will apply the IPO proceeds toward clinical development of its pipeline of internally discovered and wholly owned cancer drugs. Iambic also has R&D alliances with companies such as Bayer…
-
The Trump administration is doubling down on health care fraud investigations
The Department of Justice has a warning for health care executives: Don’t be another Theranos. As the Trump administration continues its fight against Medicare and Medicaid fraud, it is also expanding its investigations into corporate…
-
Mass. lawmaker Auchincloss favors boosting U.S. biotech over targeting China
Rep. Jake Auchincloss (D-Mass.) has some advice for fellow lawmakers: unapologetically support the biotech industry, vilify insurance companies, and focus on making America a biotech research haven, instead of relying on protectionism…
-
Belgian startup revives Galapagos CAR-T research
Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.
-
STAT+: Former FDA commissioners Califf, Gottlieb, Sharpless lay into current HHS leadership
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. It’s the last day of the STAT…
-
STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. I, too, wanted to express how devastated I am over losing our colleague Helen Branswell . She was kind, scrupulous…
-
After a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forward
When drugmakers Merck and Moderna announced promising results in August from a late-stage trial of adding an mRNA cancer vaccine to immunotherapy, it was heralded as potentially powerful new way of fighting tumors. But the data don’t show…
-
FDA ‘reset’ continues with new plan for reviewing rare disease drugs
A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.
-
Why the Future of Healthcare Depends on Reinventing Primary Care Access
What is needed is a fundamentally different operating model for primary care, one designed around continuous engagement rather than episodic encounters. The post Why the Future of Healthcare Depends on Reinventing Primary Care Access…
-
STAT+: Pharmalittle: We’re reading about former FDA head calling DOGE a ‘disaster,’ an AstraZeneca AI deal, and more
Top of the morning to you. And a fine one it is. Lots of sunshine and clear blue skies are greeting us as we prepare for another day on the road, which means we are as busy as ever hunting and gathering items of interest, as well as an…
-
STAT+: ‘AI sandboxes’ are all the rage. Advocates scramble to control their future
Y ou’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Good morning health tech readers! Day…
-
Kenya reports second Ebola case
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here . Missed the first day of Summit, but want to tune into day two? Register here . Read the rest… © Michel Lunanga/Getty Images)
-
The Role of Hospital Stewardship to Improve Outcomes and Manage Costs
[Sponsored] Panelists in the webinar, sponsored by Inovalon, will explore how near real-time surveillance, smart risk prioritization, and closed-loop intervention are shifting stewardship programs to proactive, technology-enabled…
-
STAT+: On Wall Street, there’s trouble stirring for biotech
This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content. Biotech investors were happy with the…
-
Opinion: MyChart said I could opt out of sharing my health data. Figuring out how was maddening
STAT is co-publishing this investigation by CalMatters / The Markup . Shira Fischer, a physician who works in health policy in Boston, sought a speech pathologist for her child in 2022, when virtual appointments became the norm because of…
-
Opinion: My daughter’s death changed how I understood the nursing shortage
I have spent my career studying nurses and why that workforce so often fails the people it is meant to serve. But my understanding of the system changed deeply the day my daughter died . She was 21 years old. She had intellectual and…
-
Forty percent of high school students report binge eating in new CDC survey
About 40% of high school students reported binge eating in the past month in a large new government survey , putting a spotlight on how widespread this common form of disordered eating is among young people in the U.S. This is the first…
-
Position: Hippocampal Explicit Memory Is the Cornerstone for AGI
arXiv:2606.11245v2 Announce Type: replace-cross Abstract: Large Language Models (LLMs) have demonstrated remarkable capabilities across various tasks, raising expectations for Artificial General Intelligence (AGI). This position paper…
-
Riding the Fixed-Point Curve: Image Classification in the Continuous Thought Machine
arXiv:2610.19220v1 Announce Type: cross Abstract: The Continuous Thought Machine (CTM) is a recurrent network that attends to inputs and makes predictions based on the synchronization between its neurons. On tasks spanning many domains, it…
-
How Long Is the Coast of a Neuron? Resolution-Dependent Interaction Order and Computational Capacity
arXiv:2610.19487v1 Announce Type: cross Abstract: Mandlebrot's coastline paradox reframes measurement as a joint property of an object and its ruler. Here we ask how observational resolution shapes the apparent structure of neural…
-
Design and Analysis of Temporal Representations in Neural Networks
arXiv:2610.19730v1 Announce Type: new Abstract: The ability to represent temporal information is often hypothesized to underlie the efficiency and learning capabilities of biological neural networks. This motivates the development of…
-
Controlling the latency in temporal coded spiking models for neuromorphic datasets
arXiv:2610.19732v1 Announce Type: new Abstract: Exploiting temporal information in datasets with high temporal dependencies (such as spoken keyword recognition) by spiking models is still an open problem. Promising frameworks include…
-
Iambic, an AI drug discovery specialist, banks $150M in an IPO
Part of a wave of young biotechs employing AI to accelerate research, the company claimed in regulatory filings that its approach has the potential to “disrupt legacy drug discovery paradigms.”
-
Compass Pathways CEO: Psychedelics company will ‘go slow before we go fast’
The CEO of Compass Pathways said Wednesday that the company, which is preparing to complete the submission of its psychedelic therapy for regulatory review this quarter, will “go slow before we go fast,” warning that negative patient or…
-
Structural variant detection across sequencing technologies
Nature Biotechnology, Published online: 15 October 2026; doi:10.1038/s41587-026-03332-9 HitSV models the interaction between genomic repetitiveness and signature intensity to improve structural variant detection.